US 11,981,724 B2
DNA antibody constructs for use against middle east respiratory syndrome coronavirus
David Weiner, Merion, PA (US); Trevor R F Smith, San Diego, CA (US); and Kar Muthumani, Cherry Hill, NJ (US)
Assigned to The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed by THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US); and INOVIO PHARMACEUTICALS, INC., Plymouth Meeting, PA (US)
Filed on Dec. 23, 2021, as Appl. No. 17/560,727.
Application 17/560,727 is a continuation of application No. 16/651,435, granted, now 11,230,592, previously published as PCT/US2018/053044, filed on Sep. 27, 2018.
Claims priority of provisional application 62/564,177, filed on Sep. 27, 2017.
Prior Publication US 2022/0112271 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/10 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/10 (2013.01) [C12N 15/63 (2013.01)] 14 Claims
 
1. A method of treating a MERS-CoV virus infection in a subject, the method comprising administering to the subject a nucleic acid molecule encoding one or more synthetic antibodies, wherein the nucleic acid molecule comprises at least one selected from the group consisting of:
a) a nucleotide sequence encoding SEQ ID NO:2; and
b) a nucleotide sequence encoding a fragment of an anti-MERS-CoV synthetic antibody comprising at least one selected from an anti-MERS dMAB heavy chain comprising an amino acid sequence of SEQ ID NO:5 and an anti-MERS dMAB light chain comprising an amino acid sequence of SEQ ID NO:7.